Archives

  • 2018-07
  • 2018-10
  • 2018-11
  • 2019-04
  • 2019-05
  • 2019-06
  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2019-12
  • 2020-01
  • 2020-02
  • 2020-03
  • 2020-04
  • 2020-05
  • 2020-06
  • 2020-07
  • 2020-08
  • 2020-09
  • 2020-10
  • 2020-11
  • 2020-12
  • 2021-01
  • 2021-02
  • 2021-03
  • 2021-04
  • 2021-05
  • 2021-06
  • 2021-07
  • 2021-08
  • 2021-09
  • 2021-10
  • 2021-11
  • 2021-12
  • 2022-01
  • 2022-02
  • 2022-03
  • 2022-04
  • 2022-05
  • 2022-06
  • 2022-07
  • 2022-08
  • 2022-09
  • 2022-10
  • 2022-11
  • 2022-12
  • 2023-01
  • 2023-02
  • 2023-03
  • 2023-04
  • 2023-05
  • 2023-06
  • 2023-07
  • 2023-08
  • 2023-09
  • 2023-10
  • 2023-11
  • 2023-12
  • 2024-01
  • 2024-02
  • 2024-03
  • 2024-04

    • buy aminopyridine ERS and BrS are thought to represent manif

    2019-06-06

    ERS and BrS are thought to represent 2 manifestations of the JWSs. Both syndromes are associated with vulnerability to development of polymorphic VT and VF leading to SCD [1–3,15] in young adults with no apparent structural buy aminopyridine disease and occasionally to sudden infant death syndrome [25–27]. The region generally most affected in BrS is the anterior right ventricular outflow tract (RVOT); in ERS, it is the inferior region of the left ventricle (LV) [2,4,28–32]. As a consequence, BrS is characterized by accentuated J waves appearing as a coved-type ST-segment elevation in the right precordial leads V1−V3, whereas ERS is characterized by J waves, Jo elevation, notch or slur of the terminal part of the QRS, and ST segment or Jt elevation in the lateral (type 1), inferolateral (type 2), or inferolateral þ anterior or right ventricular (RV) leads (type III) [15]. An ERP is often encountered in ostensibly healthy individuals, particularly in young males, black individuals, and athletes. ERP is also observed in acquired conditions, including hypothermia and ischemia [15,33,34]. When associated with VT/VF in the absence of organic heart disease, ERP is referred to as ERS. The prevalence of BrS with a type 1 ECG in adults is higher in Asian countries, such as Japan (0.15–0.27%) [35,36] and the Philippines (0.18%) [37], and among Japanese-Americans in North America (0.15%) [38] than in western countries, including Europe (0%–0.017%) [39–41] and North America (0.005–0.1%) [42,43]. In contrast, the prevalence of an ERP in the inferior and/or lateral leads with a J-point elevation ≥0.1mV ranges between 1% and 24% and for J-point elevation ≥0.2mV ranges between 0.6% and 6.4% [44–46]. No significant regional differences in the prevalence of an ERP have been reported [47]. However, ERP is significantly more common in blacks than in Caucasians. Little in the way of regional differences in the manifestation of ERS has been reported. ERP appears to be more common in Aboriginal Australians than in Caucasian Australians [48].
    Updates on the diagnosis of BrS According to the 2013 consensus statement on inherited cardiac arrhythmias [8] and the 2015 guidelines for the management of patients with ventricular arrhythmias and prevention of SCD [9]: “BrS is diagnosed in patients with ST- segment elevation with type 1 morphology ≥2mm in ≥1 lead among the right precordial leads V1, V2, positioned in the 2nd, 3rd or 4th intercostal space occurring either spontaneously or after provocative drug test with intravenous administration of Class I antiarrhythmic drugs. BrS is diagnosed in patients with type 2 or type 3 ST-segment elevation in ≥1 lead among the right precordial leads V1, V2 positioned in the 2nd, 3rd or 4th intercostal space when a provocative drug test with intravenous administration of Class I antiarrhythmic drugs induces a type I ECG morphology.” The present Task Force is concerned that this could result in overdiagnosis of BrS, particularly in patients displaying a type 1 ECG only after a drug challenge. Data suggest the latter population is at very low risk and that the presumed false- positive rate of pharmacologic challenge is not trivial [49]. Although a rigorous process was undertaken to establish the preceding guidelines, there remains no gold standard for establishing a diagnosis, particularly in patients with weak evidence of disease. Accordingly, we recommend adoption of the following diagnostic criteria and score system for BrS. Consistent with the recommendation of the 2013 and 2015 guidelines, only a type 1 (“coved-type”) ST-segment elevation is considered diagnostic of BrS (Fig. 1), and BrS is characterized by ST-segment elevation ≥2mm (0.2mV) in ≥1 right precordial leads (V1−V3) positioned in the 4th, 3rd, or 2nd intercostal space. However, as a departure from the guidelines, this consensus report recommends that when a type 1 ST-segment elevation is unmasked using a sodium channel blocker (Table 1), diagnosis of BrS should require that the patient also present with 1 of the following: documented VF or polymorphic VT, syncope of probable arrhythmic cause, a family history of SCD at o45 years old with negative autopsy, coved-type ECGs in family members, or nocturnal agonal respiration. Inducibility of VT/VF with 1 or 2 premature beats supports the diagnosis of BrS under these circumstances [50].